



Thread by @cryptonephilim: Health officials from China, Korea, India, Taiwan, Malaysia, Bahrain, Turkey, Jordan, United Arab Emirates, Qatar, Morocco, Algeria, Nigeria...

Health officials from China, Korea, India, Taiwan, Malaysia, Bahrain, Turkey, Jordan, United Arab Emirates, Qatar, Morocco, Algeria, Nigeria, Senegal, Cuba, Italy, and 65 scientific studies have shown hydroxychloroquine is effective when used early against COVID19. A thread.



Daily new confirmed COVID-19 deaths per million people

Shown is the rolling 7-day average. Limited testing and challenges in the attribution of the cause of death means that the number of confirmed deaths may not be an accurate count of the true number of deaths from COVID-19.



On February 17th, Chinese health officials said that chloroquine was selected out of "tens of thousands of existing drugs after multiple rounds of screening" as the most effective treatment against COVID19.

Antimalarial drug confirmed effective on COVID-19

Source: Xinhua 2020-02-17 21:07:01 Editor: huaxia



BEIJING, Feb. 17 (Xinhua) -- Chinese experts, based on the result of clinical trials, have confirmed that Chloroquine Phosphate, an antimalarial drug, has a certain curative effect on the novel coronavirus disease (COVID-19), a Chinese official said here Monday.

The experts have "unanimously" suggested the drug be included in the next version of the treatment guidelines and applied in wider clinical trials as soon as possible, Sun Yanrong, deputy head of the China National Center for Biotechnology Development under the Ministry of Science and Technology (MOST), said at a press conference.

Chloroquine Phosphate, which has been used for more than 70 years, was selected from tens of thousands of existing drugs after multiple rounds of screening, Sun said.

According to her, the drug has been under clinical trials in over 10 hospitals in Beijing, as well as in south China's Guangdong Province and central China's Hunan Province, and has shown fairly good efficacy.

In the trials, the groups of patients who had taken the drug have shown better indicators than their parallel groups, in abatement of fever, improvement of CT images of lungs, the percentage of patients who became negative in viral nucleic acid tests and the time they need to do so, she said.

Patients taking the drug also take a shorter time to recover, she added.

Sun gave an example of a 54-year-old patient in Beijing, who was admitted to hospital four days after showing symptoms. After taking the drug for a week, he saw all indicators improve and the nucleic acid turn negative.

So far, no obvious serious adverse reactions related to the drug have been found among the over 100 patients enrolled in the clinical trials, she said.

On February 13th, Korea posted their official treatment guidelines utilizing hydroxychloroquine as a treatment for COVID19.

Hydroxychloroquine used by Korea for Covid-19 while US is divided

APR 27, 2020, 9:52 PM

South Korea recommended the anti-malarial drug HCQ to treat Covid-19 while political interference in the US over the drug has alarmed medical experts

FACEBOOK

TWITTER

EMAIL

PRINT

1,997 SHARES

4 COMMENTS

Please note that the posts on The Blogs are contributed by third parties. The opinions, facts and any media content in them are presented solely by the authors, and neither The Times of Israel nor its partners assume any responsibility for them. Please contact us in case of abuse. In case of abuse,

[Report this post.](#)

drug has alarmed medical experts



A box of Plaquenil, Sanofi's commercial name for the anti-malaria drug hydroxychloroquine. Used for years to treat malaria and autoimmune disorders, HCQ could also be an important Covid-19 drug. (AFP / Alain Pitton/NurPhoto)

Hydroxychloroquine (HCQ), a well-known anti-malarial drug that has been around for decades, is now a political football between the Trump administration and Democrats during an election year in the United States.

US President Donald Trump has repeatedly touted the drug and received significant pushback from the media and the Democratic Party, with the governors of [Nevada](#), [Michigan](#) and [New York](#) even going so far as to issue executive orders restricting how doctors can use HCQ to treat patients suffering from Covid-19.

Medical treatments have traditionally been a private decision between patients and doctors, but now it seems politicians are usurping their right to choose. According to Dr Jeffrey Singer, a general surgeon and Cato Institute fellow, this [threatens the integrity](#) of the medical profession and indirectly imperils patients, by denying them emergency options when no other alternatives are available.

Moreover, the politicization of treatment options would not help Americans, given the fact countries such as Belgium, France and South Korea have used HCQ to treat Covid-19 with a good degree of success.

South Korea was one of the first countries to be hit by the virus after China, reporting its first case on January 20 and peaking by late February, before suddenly tapering off in early March and “flattening the curve.” It also has a comparatively low mortality rate through a combination of testing, tracing, containment and [HCQ](#).

South Korea experts recommend anti-HIV, anti-malaria drugs for COVID-19

By [Elizabeth Shim](#)



South Korean medical experts are recommending the use of various drugs for more serious cases of COVID-19. Photo by Thomas Maresca/UPI | [License Photo](#)

March 12 (UPI) -- South Korean disease experts have begun to recommend the use of a combination of antiviral and anti-malaria drugs for patients of the new strain of coronavirus.

Kwon Jun-wook, deputy head of the Korea Centers for Disease Control and Prevention, said Thursday at a regular press briefing the recommendations come from multiple groups, and that the government is ready to apply the recommendations to patients "where necessary," Newsis reported.

The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, Korean Society of Pediatric Infectious Diseases and a tuberculosis association published their recommendations on Thursday.

The groups advised discretion among medical professionals, while recommending the administration of Kaletra, an anti-HIV medication that includes the drugs lopinavir and ritonavir.


RELATED [Saudi Arabia extends travel ban to EU amid COVID-19 fears](#)

Kaletra blocks the ability of HIV to replicate itself, and also inhibits the growth of cancer cells.

South Korean experts are also recommending the use of hydroxychloroquine in combination with the anti-HIV medication. HCQ is sold under the brand name Plaquenil, among others, and is used for the prevention and treatment of malaria.

Daily new confirmed COVID-19 deaths per million people


Shown is the rolling 7-day average. Limited testing and challenges in the attribution of the cause of death means that the number of confirmed deaths may not be an accurate count of the true number of deaths from COVID-19.



Source: European CDC - Situation Update Worldwide - Last updated 28 July, 11:07 (London time), Our World In Data CC BY
▶ Mar 2, 2020 Jul 28, 2020

Case fatality rate of the ongoing COVID-19 pandemic

The Case Fatality Rate (CFR) is the ratio between confirmed deaths and confirmed cases. During an outbreak of a pandemic the CFR is a poor measure of the mortality risk of the disease. We explain this in detail at [OurWorldInData.org/Coronavirus](https://ourworldindata.org/coronavirus)



Source: European CDC - Situation Update Worldwide - Last updated 28 July, 11:07 (London time) CC BY
▶ Jan 19, 2020 Jul 28, 2020

The Health Minister of Qatar in an interview with Al Jazeera said that Qatar is using hydroxychloroquine with "great success" and has a relatively low case fatality rate compared to other nations.

Hydroxychloroquine is currently being used with great success – Qatar has a case fatality rate of only 0.04% with 21 deaths out of 43,714 cases.

Source: Al Jazeera



It has been nearly two months since Qatar implemented a series of measures to contain the outbreak of COVID-19, the highly infectious respiratory disease caused by the novel coronavirus.


The government has since closed schools, issued stay-at-home orders and imposed travel bans on travellers from many countries. But while infection rates continue to rise, the number of deaths here remains low.

On Talk to Al Jazeera, we speak to Qatar's minister of public health, Dr Hanan Mohamed al-Kuwari, about the government's efforts to tackle the COVID-19 pandemic.

Case fatality rate of the ongoing COVID-19 pandemic

Our World in Data

The Case Fatality Rate (CFR) is the ratio between confirmed deaths and confirmed cases. During an outbreak of a pandemic the CFR is a poor measure of the mortality risk of the disease. We explain this in detail at [OurWorldInData.org/Coronavirus](https://ourworldindata.org/coronavirus)



Health officials in Algeria have claimed to have "great success" using hydroxychloroquine in combination with antibiotics and have "not noted any adverse reactions"

among several thousand patients who have been given the treatment.

Covid-19: Algeria and Morocco continue using chloroquine despite concerns



Moroccan health minister Khalid Ait Taleb says use of chloroquine leads to faster recovery


Health authorities in Algeria and Morocco say they intend to continue treating Covid-19 patients with anti-malaria drugs despite safety concerns raised by the World Health Organisation (WHO).

Algeria claims to have had "great success" using hydroxychloroquine in combination with antibiotics and says it has "not noted any adverse reactions" among several thousand patients who have been given this treatment.

Daily new confirmed COVID-19 deaths per million people

Shown is the rolling 7-day average. Limited testing and challenges in the attribution of the cause of death means that the number of confirmed deaths may not be an accurate count of the true number of deaths from COVID-19.

LINEAR LOG



Nigeria has found success with using hydroxychloroquine as a prophylaxis for COVID19.

COVID-19: Nigerian study finds Chloroquine, Hydroxychloroquine effective as Prophylaxis

ON JUNE 23, 2020 5:45 PM / IN HEALTH, NEWS /

Kindly Share This Story:






By Chioma Obinna

Preliminary trials on the use of chloroquine and hydroxychloroquine as prophylaxis for COVID-19 in Nigeria has recorded some level of success.

The study protocol, sponsored by LiveWell Initiative in collaboration with frontline healthcare workers in Nigeria, has undergone hypothesis testing among physicians, researchers, pharmacists, and clinicians with online debates on several professional health platforms.

Daily new confirmed COVID-19 deaths per million people

Shown is the rolling 7-day average. Limited testing and challenges in the attribution of the cause of death means that the number of confirmed deaths may not be an accurate count of the true number of deaths from COVID-19.



In March, Health Officials from Senegal found "no complications and no deaths in patients treated with hydroxychloroquine". They said they will continue treatment with hydroxychloroquine.

Coronavirus: first assessment of the use of hydroxychloroquine in Senegal



Published on : 05/03/2020 - 01:22 Modified : 05/04/2020 - 13:55



The controversial chloroquine and its derivative, hydroxychloroquine, are currently being tested in several countries, alongside other molecules, against Covid-19. GERARD JULIEN / AFP


Text by: [RFI](#) [To follow](#) ⌚ 2 min

In Senegal, the first preliminary results of the study on the use of chloroquine to treat patients with the coronavirus are now known. The molecule was prescribed to certain patients at Fann hospital in Dakar by Professor Moussa Seydi. On May 2, the doctor released his initial findings. According to a sample of 181 patients, hydroxychloroquine would allow faster healing.

With our correspondent in Dakar, William de Lesseux


In the panel of 181 patients cared for by **Moussa Seydi**, all the patients survived. This sample was divided into three categories. The first type of patient corresponds to the controls, those who did not take hydroxychloroquine. Half of them were released from the hospital after 13 days.

Then there are those who have been prescribed the molecule. With chloroquine healing is faster. It takes eleven days, or 48 hours less for half of these patients, to eradicate the virus. Finally, a final minority group was administered, in addition, azithromycin. It is an antibiotic to prevent superinfection. These left the hospital after only nine days, explains Moussa Seydi. For him, these results are still preliminary but satisfactory.



" In all the patients who received treatment with hydroxychloroquine and who consulted early, no complications were noted, even fewer cases of death," he said. We will continue our treatment with hydroxychloroquine and azithromycin " .

Pr Seydi delivers the figures for Hydroxychloroquine's "victory" over Covid-19 ... no complications, no deaths




On the front line in the face of the Covid-19 epidemic, Professor Moussa Seydi, infectious disease specialist and head of the Center for Infectious Diseases at Fann Hospital in Dakar, chose, from the first cases, to use a treatment based on chloroquine to facilitate the recovery of the patients for whom it is responsible. This Saturday, May 02, 2020, he reaffirmed the effectiveness of hydroxychloroquine in the treatment of patients infected with covid-19, during a monthly update.

" In a study of 181 patients, the median length of hospital stay was 13 days for patients without any treatment. These median times were 11 days in patients who took hydroxychloroquine alone, and 9 days in patients who took hydroxychloroquine in combination with Azithromycin ", Argued Professor Seydi, before evoking the fruit of his first observations which seem rather encouraging.

No complications and no deaths in patients treated with chloroquine

Daily new confirmed COVID-19 deaths per million people

Shown is the rolling 7-day average. Limited testing and challenges in the attribution of the cause of death means that the number of confirmed deaths may not be an accurate count of the true number of deaths from COVID-19.



Cuban Medical Authorities have found "early hydroxychloroquine potent against COVID19". Health officials are using low doses of the antimalarial drug to effectively treat patients in the early stages of the disease.

Cuba: Early hydroxychloroquine potent against COVID-19

Cuba uses hydroxychloroquine and some other unique drugs in treatment of coronavirus, say Cuban medical authorities

Vakkas Dogantekin | 10.07.2020



Coronavirus

US: Florida man uses coronavirus aid to buy Lamborghini

Brazilian unions urge ICC to investigate government

Turkey repatriates nationals from Mozambique

Coronavirus report says 21 US states in 'red zone'

COVID-19 claims 77 more lives in Iraq



ANKARA


Health authorities in Cuba are using low doses of the antimalarial drug hydroxychloroquine to effectively treat COVID-19 patients in the early stages of the disease.

"We do use hydroxychloroquine in the framework of the protocol for management of coronavirus patients," Dr. Augustin Lage Davila, advisor to the president of BioCubaFarma and former director of the Centre for Molecular Immunology in Havana, told Anadolu Agency on Thursday.



Daily new confirmed COVID-19 deaths per million people

Shown is the rolling 7-day average. Limited testing and challenges in the attribution of the cause of death means that the number of confirmed deaths may not be an accurate count of the true number of deaths from COVID-19.



Costa Rica has been using hydroxychloroquine to treat early since a teleconference with health officials from China on March 18th. They now boast one of the lowest fatality rates in the world.

Hydroxychloroquine: The Drug Costa Rica Uses Successfully To Fight Covid-19



By Rico

19 April 2020

126251

Like 48K



Modified date: 19 April 2020

Used in the world for decades in the treatment of malaria, a month ago, the Caja Costarricense de Seguro Social (CCSS) decided to apply hydroxychloroquine to patients infected with the new coronavirus until a vaccine is available.





On April 14, the Swiss company Novartis donated to the CCSS a shipment of 108,000 hydroxychloroquine tablets.

This immunosuppressant drug is produced in Costa Rica.

The medical director of the Caja, Mario Ruiz, as the director of Pharmacoepidemiology, Marjorie Obando Elizondo, the director of the Children's Hospital, Olga Arguedas and the minister of Health, Daniel Salas, confirmed the use of the drug and the success in mitigating and containing the progression of the virus and also in reducing the number of patients who must be hospitalized in intensive care units.

"In Costa Rica we have been applying hydroxychloroquine since we had a meeting by teleconference with personnel in China who attended the emergency in the cities of Shanghai and Wuhan," explained Ruiz.

That videoconference, offered by the Chinese Embassy in Costa Rica, took place on the night of March 18. It included, among others, the director-general and the director of epidemiology of the Chinese Center for Disease Control and Prevention (briefly as **China CDC**).




On March 18, a videoconference was held between the health authorities of Costa Rica and China. Costa Ricans talked from the Huawei center, west of San José, thanks to the help of the Chinese Embassy. (Photo Embassy of China)

"We decided to ask for help from those who have gone through this. The experts from Shanghai and Wuhan gave us recommendations for patient management. We were told that it is key that a mild or moderate patient does not become severe. They explained that they used hydroxychloroquine for this, **but never azithromycin** (an antibiotic for respiratory infections) due to the associated cardiac complications," Ruiz said.

Case fatality rate of the ongoing COVID-19 pandemic

The Case Fatality Rate (CFR) is the ratio between confirmed deaths and confirmed cases. During an outbreak of a pandemic the CFR is a poor measure of the mortality risk of the disease. We explain this in detail at [OurWorldInData.org/Coronavirus](https://ourworldindata.org/coronavirus)



On March 29th, Italy finally began mass treatment with hydroxychloroquine. Italy's death rate peaked a few days later and has continued to drop since then.

Italy Finally Starts Mass Treatment with Hydroxychloroquine

© March 29, 2020 10:40 pm



Doctors in Italy have finally begun widely prescribing hydroxychloroquine in certain combinations in Rome and the wider region of Lazio with a population of around six million.

According to Corriere della Sera, a well known Italian daily newspaper, Dr. Pier Luigi Bartoletti, Deputy National Secretary of the Italian Federation of General Practitioners, explains that every single person with Covid-19 that has early signs, like a cough or a fever for example, is now being treated with the anti-malaria drug.

The drug “is already giving good results,” Bartoletti [says](#) while Malaysia [reveals](#) they have been using it since the very beginning. Bartoletti further adds that the drug:


“Must be used with all the necessary precautions, it must be evaluated patient by patient. It can have side effects. But those that take it are responding really well.

POPULAR



Daily new confirmed COVID-19 deaths per million people

Shown is the rolling 7-day average. Limited testing and challenges in the attribution of the cause of death means that the number of confirmed deaths may not be an accurate count of the true number of deaths from COVID-19.



On April 2nd, a global survey of 6,000 doctors from 30 countries found hydroxychloroquine as the "most effective therapy" from a list of 15 options.

Hydroxychloroquine rated 'most effective therapy' by doctors for coronavirus: Global survey

Drug known for treating malaria used by U.S. doctors mostly for high-risk COVID-19 patients



Gopesh Patel, RPh, with VLS Pharmacy in Brooklyn, has filled physician prescriptions for more than 70 COVID-19 patients, supplying a compounded formulation with hydroxychloroquine. (Business Wire via Associated Press) ****FILE**** [more >](#)



Print

By Valerie Richardson - The Washington Times - Thursday, April 2, 2020

An international poll of more than 6,000 doctors released Thursday found that the antimalarial drug hydroxychloroquine was the most highly rated treatment for the novel coronavirus.

The survey conducted by Sermo, a global health care polling company, of 6,227 physicians in 30 countries found that 37% of those treating COVID-19 patients rated hydroxychloroquine as the "most effective therapy" from a list of 15 options.

In July, a professor of epidemiology at Yale wrote a paper claiming that "the data fully supports hydroxychloroquine" and the anti-malarial drug "is the key to defeating COVID19". He argued that "tens of thousands of patients are dying unnecessarily without the drug"

Follow Us    

Search

 **SIGN UP FOR OUR DAILY NEWSLETTERS**

enter address...

Submit

[Manage Newsletters](#)

FRONT PAGE PODCAST

 THE WASHINGTON TIMES FRONT PAGE
July 28, 2020

00:00:00



RECOMMENDED



Source for Steele discredited anti-Trump dossier outed



Quiz: Name the famous inventors of these revolutionary product



Trump officials focus how, and not whether schools reopen



Quiz: Can you guess th

Yale epidemiologist says hydroxychloroquine is 'the key to defeating COVID-19'

'Tens of thousands of patients with COVID-19 are dying unnecessarily' without the drug, he argues.



By Daniel Payne



Updated: July 25, 2020 - 3:47pm

Article

Dig In

An Ivy League epidemiology professor is claiming that hydroxychloroquine — the drug that has been at the center of a politicized medical debate for the last several months — is "the key to defeating COVID-19," and that medical officials should be widely prescribing it to save the lives of thousands of coronavirus patients.

Harvey Risch, a professor of epidemiology at Yale as well as the director of that school's Molecular Cancer Epidemiology Laboratory, argues in a [Newsweek op-ed](#) this week that "the data fully support" the wide use of hydroxychloroquine as an effective treatment of COVID-19.

"When this inexpensive oral medication is given very early in the course of illness, before the virus has had time to multiply beyond control, it has shown to be highly effective," Risch argues in the column.

TOP STORIES

COURTS & LAW



At least one protester at McCloskey altercation was armed with firearm, sources say

RUSSIA AND UKRAINE SCANDALS



Congressman: DOJ could pursue treason charges over Russia probe misconduct

CULTURE



Joe Piscopo: 'Ebony and Ivory' sketch with Eddie Murphy would be taboo now, due to 'cancel culture'

CONGRESS



Cruz introduces Senate bill to block COVID-19 funding for states

In April, The American Physicians and Surgeons (AAPS) wrote a letter saying that peer reviewed studies since January have provided clear and convincing evidence that HCQ may be beneficial in treating COVID19. In observational studies of 2137 patients, 91.6% improved clinically.

Hydroxychloroquine Has about 90 Percent Chance of Helping COVID-19 Patients, States Association of American Physicians and Surgeons (AAPS)



GlobeNewswire April 28, 2020

TUSCON, Ariz., April 28, 2020 (GLOBE NEWSWIRE) -- In a [letter to Gov. Doug Ducey](#) of Arizona, the Association of American Physicians and Surgeons (AAPS) presents a [frequently updated table](#) of studies that report results of treating COVID-19 with the anti-malaria drugs chloroquine (CQ) and hydroxychloroquine (HCQ, Plaquenil®).

To date, the total number of reported patients treated with HCQ, with or without zinc and the widely used antibiotic azithromycin, is 2,333, writes AAPS, in observational data from China, France, South Korea, Algeria, and the U.S. Of these, 2,137 or 91.6 percent improved clinically. There were 63 deaths, all but 11 in a single retrospective report from the Veterans Administration where the patients were severely ill.

The antiviral properties of these drugs have been studied since 2003. Particularly when combined with zinc, they hinder viral entry into cells and inhibit replication. They may also prevent overreaction by the immune system, which causes the cytokine storm responsible for much of the damage in severe cases, explains AAPS. HCQ is often very helpful in treating autoimmune diseases such as lupus and rheumatoid arthritis.

Additional benefits shown in some studies, AAPS states, is to decrease the number of days when a patient is contagious, reduce the need for ventilators, and shorten the time to clinical recovery.

[Peer-reviewed studies](#) published from January through April 20, 2020, provide clear and convincing evidence that HCQ may be beneficial in COVID-19, especially when used early, states AAPS. Unfortunately, although it is perfectly legal to prescribe drugs for new indications not on the label, the Food and Drug Administration (FDA) has said that CQ and HCQ should be used for COVID-19 only in hospitalized patients in the setting of a clinical study if available. Most states are making it difficult for physicians to prescribe or pharmacists to dispense these medications.

There are now 65 hydroxychloroquine studies that show high effectiveness as an early treatment against COVID19, while late treatment shows mixed results. Hydroxychloroquine has been safely prescribed to hundreds of millions since 1955. The CDC website literally says that it can be "safely taken by pregnant women and children". The WHO list it as an essential medicine.

Medicines for the Prevention of Malaria While Traveling

Hydroxychloroquine (Plaquenil™)

What is hydroxychloroquine?

Hydroxychloroquine (also known as hydroxychloroquine sulfate) is an arthritis medicine that also can be used to prevent malaria. It is available in the United States by prescription only. It is sold under the brand name Plaquenil and it is also sold as a generic medicine. It is available in tablets of 155mg base (200mg salt).

You should know that the 155mg base tablet is the same as the 200mg salt tablet. It is just two different ways of describing the same thing.

Hydroxychloroquine can be prescribed for either prevention or treatment of malaria.

This fact sheet provides information about its use for the prevention of malaria infection associated with travel.



Who can take hydroxychloroquine?

Hydroxychloroquine can be prescribed to adults and children of all ages. It can also be safely taken by pregnant women and nursing mothers.

Who should not take hydroxychloroquine?

People with psoriasis should not take hydroxychloroquine.

How should I take hydroxychloroquine?

Both adults and children should take one dose of hydroxychloroquine per week starting at least 1 week before traveling to the area where malaria transmission occurs. They should take one dose per week while there, and for 4 consecutive weeks after leaving.

The weekly dosage for adults is 310mg base (400mg salt).

Your doctor will have calculated the correct weekly dose for your child based on the child's weight. The child's dose should not exceed the adult dose of 310mg base (400mg salt) per week


Where can I buy hydroxychloroquine?

Antimalarial drugs are available in the United States by prescription only. Medicines should be obtained at a pharmacy before travel rather than in the destination country. Buying medications abroad has its risks: the drugs could be of poor quality, contaminated, or counterfeit and not protect you against malaria.

In what parts of the world can hydroxychloroquine be used for prevention of malaria in travelers?

Hydroxychloroquine can only be used in places where chloroquine (a related medicine) is still effective. There are only a few places left in the world where hydroxychloroquine is still effective including parts of Central America and the Caribbean.

CDC keeps track of all the places in the world where malaria transmission occurs and which malaria drugs that are recommended for use in each place. This information can be found using the malaria map on the CDC website: <http://www.cdc.gov/malaria/map/index.html>.



Center for Global Health
Division of Parasitic Diseases and Malaria



darunavir	20	fluphenazine	49
dasabuvir	22	folic acid	35
dasatinib	32	fomepizole	5
daunorubicin	29	fosfomycin	15
deferoxamine	5, 35	fresh-frozen plasma	36
delamanid	17	furosemide	38, 40
dengue vaccine	46	gemcitabine	30
desmopressin	35	gentamicin	11, 46
dexamethasone	3, 4, 33, 41, 49	glecaprevir + pibrentasvir	22
dextran 70	36	gliclazide	43
diaphragms	48	glucagon	43
diazepam	3, 5, 50	glucose	51
diazoxide	43	glucose with sodium chloride	51
diethylcarbamazine	6	glutaral	40
digoxin	37, 38	glyceryl trinitrate	37
dihydroartemisinin + piperazine phosphate	24	griseofulvin	18
diloxanide	23	Haemophilus influenzae type b vaccine	45
dimercaprol	5	haloperidol	3, 50
diphtheria antitoxin	44	halothane	1
diphtheria vaccine	45	heparin sodium	35
docetaxel	29	hepatitis A vaccine	46
docusate sodium	3	hepatitis B vaccine	45
dolutegravir	20	HPV vaccine	45
dolutegravir + lamivudine + tenofovir	20	hydralazine	37
dopamine	38	hydrochlorothiazide	37, 38, 40, 41
doxorubicin	29	hydrocortisone	4, 33, 39, 42, 43
doxycycline	11, 24, 25	hydroxocobalamin	35
efavirenz (EFV or EFZ)	19	hydroxycarbamide	30, 36
efavirenz + emtricitabine + tenofovir	20	hydroxychloroquine	53
efavirenz + lamivudine + tenofovir	20	hyoscine butylbromide	3
eflornithine	26	hyoscine hydrobromide	3
emtricitabine + tenofovir	21	ibuprofen	2, 26, 49
enalapril	37, 38	ifosfamide	30
enoxaparin	35	imatinib	32
entecavir	21	influenza vaccine	46
ephedrine	1	insulin injection (soluble)	43
epinephrine (adrenaline)	4, 37, 47, 51	intermediate-acting insulin	43
ergocalciferol	52	intra-peritoneal dialysis solution (of appropriate composition)	49
ergometrine	48	iodine	52
erlotinib	32	iohexol	40
erythromycin	46	ipratropium bromide	51
erythropoiesis-stimulating agents	35	irinotecan	30
estradiol cypionate + medroxyprogesterone acetate	48	isoflurane	1
ethambutol	16	isoniazid	16
ethambutol + isoniazid + pyrazinamide + rifampicin	16	isoniazid + pyrazinamide + rifampicin	16
ethambutol + isoniazid + rifampicin	16	isoniazid + pyridoxine + sulfamethoxazole + trimethoprim	21
ethanol	40	isoniazid + rifampicin	16
ethinylestradiol + levonorgestrel	47	isosorbide dinitrate	37
ethinylestradiol + norethisterone	47	itraconazole	18
ethionamide	17	ivermectin	6, 26
ethosuximide	6		
etonoqestrel-releasing implant	48		

The UVA study was a fraud. HCQ was used after patients were already severe & intubated. The group being treated with HCQ had the highest median age, were the most obese, and had the highest percentage of smokers. This is how the media covered it.

No benefits, more deaths in COVID-19 patients treated with malaria drug hydroxychloroquine: study

Chicago Tribune | 2 hours ago

A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care, researchers reported. The nationwide study was not a rigorous experiment. But with 368 patients ...



The largest survey of using a Trump-touted malaria drug to treat coronavirus patients showed no benefit

Business Insider | 5 hours ago

A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care.



Study finds more deaths, no benefit from malaria drug touted as coronavirus cure

Oregonian | 2 hours ago

Hydroxychloroquine, the malaria drug widely touted by President Donald Trump for treating the novel coronavirus, showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those given the drug versus standard care, researchers reported. The nationwide study was not a rigorous experiment.



More deaths, no benefit from malaria drug in VA virus study

Associated Press | 7 hours ago

A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths ...



Delayed death certificates interrupting municipal benefits, union leaders say

Politico | 21 hours ago

As workers begin to demand more posthumous security if they become infected with the coronavirus ... obtain death certificates that enable them to secure continued health coverage and other benefits, according to labor leaders.

"There is no death certificates right now, so not only do you have to bury at a very high rate ... you can ...



Study of Trump-Promoted Coronavirus Drug Finds More Deaths, No Benefit

The Daily Beast | 5 hours ago

The team acknowledged that patients who got hydroxychloroquine were likely to be among the most critically ill, but even accounting for that, the death rate was outside. Two other small studies, one in France and one in China, also found hydroxychloroquine was no better than standard therapies. The authors of the VA analysis said their limited ...



COVID-19 treatment hydroxychloroquine showed no benefit, more deaths in VA virus study

Fox News | 2 hours ago

Malaria drug hydroxychloroquine showed no benefit in a large study of its use in U.S. veterans hospitals, researchers say.



Hydroxychloroquine showed no benefit, more deaths for coronavirus patients who used drug

MassLive | 3 hours ago

A study backed the words of Dr. Anthony Fauci showing Hydroxychloroquine showed no benefits to patients with coronavirus.



Study finds more deaths, no benefit from malaria drug touted by President Trump

KHOU II | 4 hours ago

A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care, researchers reported. The nationwide study was not a rigorous experiment. But with 368 patients ...



NEW: Study shows no benefit from drug touted by Trump in virus fight

Atlanta Journal-Constitution | 2 hours ago

A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care.



Hydroxychloroquine test: More deaths, no benefit in VA study

Mercury News | 3 hours ago

About 28% who were given hydroxychloroquine plus usual care died, versus 11% of those getting routine care alone. About 22% of those getting the drug plus azithromycin died too, but the difference ...



Study finds more coronavirus deaths, no benefit from malaria drug touted by Trump

Philadelphia Inquirer | 5 hours ago

A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care, researchers reported. The nationwide study was not a rigorous experiment. But with 368 patients ...



Study shows more deaths, no benefit from malaria drug touted by Trump

NBC News | 2 hours ago

The research has not been reviewed by other scientists but is the largest look so far of hydroxychloroquine with or without an antibiotic for COVID-19.



More deaths, no benefit from malaria drug in VA virus study | Raleigh News & Observer

Raleigh News & Observer | 3 hours ago

A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large new study.



Coronavirus study: More deaths, no benefit from malaria drug touted by Trump

syracuse.com | 5 hours ago

A U.S. coronavirus study says a malaria drug touted by President Donald Trump as a possible COVID-19 cure showed no benefit and more deaths, according to results released Tuesday. The Associated Press reports a nationwide study conducted at VA hospitals gave hydroxychloroquine, with or without the antibiotic azithromycin, to 368 patients ...



No benefit, more deaths: Hydroxychloroquine flops in VA hospitals study

Washington Times | 2 hours ago

A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care, researchers reported. The nationwide study was not a rigorous experiment. But with 368 patients ...



More deaths, no benefit from malaria drug touted by Trump, coronavirus study finds

Tampa Bay Times | 1 hour ago

A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were mor



Veterans With COVID-19 Given Trump-Touted Hydroxychloroquine Showed No Benefits: Study Finds

Forbes | 3 hours ago

In a retrospective study, which has not yet been peer-reviewed, doctors examined patient outcomes for U.S. military veterans with COVID-19 who were given hydroxychloroquine (an anti-malaria drug touted by President Trump as coronavirus treatment) and compared them to patients who did not receive that treatment.



More deaths, no benefit from malaria drug hydroxychloroquine in VA coronavirus study

The Boston Globe | 5 hours ago

A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care, researchers reported. The nationwide study was not a rigorous experiment. But with 368 patients ...



Drug championed by Trump for coronavirus shows no benefit, possible harm in study awaiting validation

YAHOO! | 37 minutes ago

There are currently no approved treatments or vaccines specifically for the new coronavirus. An analysis of Veterans Health Administration (VA) data found that 28% of 97 patients given hydroxychloroquine along with standard care died.



A VA coronavirus study finds hydroxychloroquine results in more patient deaths

The Salt Lake Tribune | 2 hours ago

A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care, researchers



Hydroxychloroquine as treatment for COVID-19 shows no benefit and more deaths in VA study

MarketWatch | 5 hours ago

President Trump has frequently touted the malaria drug as a potential breakthrough in the ongoing coronavirus fight.



Trump-Boosted Malaria Drug Showed No Benefit in Study At Veterans Hospitals

Talking Points Memo | 6 hours ago


A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were



The Lancet Study using the data of "96,032 patients from 671 hospitals in six continents" which led to the World Health Organization suspending clinical trials citing the "danger of hydroxychloroquine" was retracted after it was discovered to be based on fabricated data.

EXCLUSIVE: The Lancet Study on Hydroxychloroquine Was a COMPLETE FRAUD

JUNE 5, 2020 · COMMENTARY · 5 MINS READ



The Lancet Medical Journal apologized this week and pulled the controversial hydroxychloroquine study.

The study released by Lancet titled — “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” — was retracted after it was found to be a **complete fraud**.

How does Africa have a lower death rate than the United States and the rest of the world?

Hydroxychloroquine.

Africans rush for chloroquine as virus

1. Business groups say omnibus bill

tsunami looms

Camille Malplat

Agence France-Presse

Libreville, Gabon / Wed, April 1, 2020 / 10:04 pm



Shoppers queue at a grocery store during a nationwide 21 day lockdown in an attempt to contain the coronavirus disease (COVID-19) outbreak in Chatsworth near Durban, South Africa, March 31, 2020. (REUTERS/Rogan Ward)

could boost worker productivity

2. Artisan Karya art raffle goes Instagram Live for final edition
3. Catholic Church excludes adult women in talks about protecting sexual abuse victims
4. Indonesia's latest official COVID-19 figures
5. Escape to North Korea: Defector at heart of COVID-19 case fled sex abuse investigation
6. ASEAN loses a third of mangroves in last 40 years
7. Childhood victims struggle to report sexual abuse in Catholic Church
8. Gold price surge blessing in disguise for Indonesia
9. Wanted: Volunteers for first human trial of COVID-19 vaccine in Indonesia
10. COVID-19: Not all hand sanitizers work against it - here's what you should use

0
SHARES



Despite loud appeals for caution, Africans are rushing to embrace chloroquine, the venerable anti-malaria drug touted as a possible treatment for coronavirus.

From hospitals in Senegal to pharmaceutical companies in South Africa and street sellers in Cameroon, chloroquine has fired hopes of a medicinal fix against a virus that is set to scythe through Africa's poorly protected countries.

Chloroquine and derivatives such as hydroxychloroquine have been used for decades as cheap and safe drugs against malaria, although their effectiveness in this field is now undermined by growing parasite resistance.

Small-scale tests in China and France -- either unpublished or outside the rigorous framework of mainstream drug trials -- suggest that chloroquine reduces virus levels in people with coronavirus.

On March 24, President Donald Trump said chloroquine could be a "gift from God" -- a comment that sparked strident criticism.

Health watchdogs have issued calls for caution until larger clinical trials are carried out, and there have been several recorded deaths from self-medication because of toxic side effects.

Despite this, in many settings across Africa, chloroquine has been placed in the front line against coronavirus.

Its rise stems partly from desperation, given Africa's meager capacity to deal with a pandemic on the scale seen in Europe or the United States.

Burkina Faso, Cameroon and South Africa have swiftly authorized hospitals to treat virus patients with the drugs.

Around half of infected people in Senegal are already being prescribed hydroxychloroquine, Moussa Seydi, a professor at Dakar's Fann Hospital, told AFP last Thursday.

Every patient who was recommended the drug accepted it, "with no exceptions," he said.

In Democratic Republic of Congo, President Felix Tshisekedi last week declared

Subscribe or log in to get unlimited access to premium content

JP

Premium Subscription

FOLLOW OUR SOCIAL MEDIA




The Jakarta Post

it was "urgent" to produce chloroquine "in industrial quantities".

Daily new confirmed COVID-19 deaths per million people

Shown is the rolling 7-day average. Limited testing and challenges in the attribution of the cause of death means that the number of confirmed deaths may not be an accurate count of the true number of deaths from COVID-19.



Peer-reviewed, retrospective analysis of 2,541 patients found "Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients"

"Our analysis shows that using hydroxychloroquine helped saves lives," said neurosurgeon Dr. Steven Kalkanis, CEO, Henry Ford Medical Group.

Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows

July 02, 2020

DETROIT - Treatment with hydroxychloroquine cut the death rate significantly in sick patients hospitalized with COVID-19 - and without heart-related side-effects, according to a new study published by Henry Ford Health System.

In a large-scale retrospective analysis of 2,541 patients hospitalized




between March 10 and May 2, 2020 across the system's six hospitals, the study found 13% of those treated with hydroxychloroquine alone died compared to 26.4% not treated with hydroxychloroquine. None of the patients had documented serious heart abnormalities; however, patients were monitored for a heart condition routinely pointed to as a reason to avoid the drug as a treatment for COVID-19.



The study was published today in the International Journal of Infectious Diseases, the peer-reviewed, open-access online publication of the International Society of Infectious Diseases (ISID.org).

Patients treated with hydroxychloroquine at Henry Ford met specific protocol criteria as outlined by the hospital system's Division of Infectious Diseases. The vast majority received the drug soon after admission; 82% within 24 hours and 91% within 48 hours of admission. All patients in the study were 18 or over with a median age of 64 years; 51% were men and 56% African American.



"The findings have been highly analyzed and peer-reviewed," said Dr. [Marcus Zervos](#), division head of Infectious Disease for Henry Ford Health System, who co-authored the study with Henry Ford epidemiologist Samia Arshad. "We attribute our findings that differ from other studies to early treatment, and part of a combination of interventions that were done in supportive care of patients, including careful cardiac monitoring. Our dosing also differed from other studies not showing a benefit of the drug. And other studies are either not peer reviewed, have limited numbers of patients, different patient populations or other differences from our patients."

Zervos said the potential for a surge in the fall or sooner, and infections continuing worldwide, show an urgency to identifying inexpensive and effective therapies and preventions.

"We're glad to add to the scientific knowledge base on the role and how best to use therapies as we work around the world to provide insight," he said. "Considered in the context of current studies on the use of hydroxychloroquine for COVID-19, our results suggest that the drug may have an important role to play in reducing COVID-19 mortality."


The study also found those treated with azithromycin alone or a combination of hydroxychloroquine and azithromycin also fared slightly better than those not treated with the drugs, according to the Henry Ford data. The analysis found 22.4% of those treated only with azithromycin died, and 20.1% treated with a combination of azithromycin and hydroxychloroquine died, compared to 26.4% of patients dying who were not treated with either medication.

"Our analysis shows that using hydroxychloroquine helped saves lives," said neurosurgeon [Dr. Steven Kalkanis](#), CEO, Henry Ford Medical Group and Senior Vice President and Chief Academic Officer of Henry Ford Health System. "As doctors and scientists, we look to the data for insight. And the data here is clear that there was benefit to using the drug as a treatment for sick, hospitalized patients."

"It has been deflating to see how the science has been

corrupted..to disparage hydroxychloroquine", said former UCLA Professor & Harvard MD, Dr. George Fareed. "By far the best tool has been the combination of hydroxychloroquine, with either azithromycin or doxycycline and zinc."

Local doctor pushing proven HCQ cocktail treatment for COVID into national debate



Source: [The Desert Review](#)

BRAWLEY – A front-line local doctor treating COVID-19 patients claims to have figured out what works to keep his patients alive. He claims to have answers on better controlling, and curbing, a pandemic that knows no boundaries.

Dr. George Fareed is a physician who can be spotted during football season as local high school's field doctor working with athletes from Holtville, El Centro, Imperial, and lately, with Brawley Union High School.

Fareed graduated with honors in 1970 at Harvard and pursued medical studies, research, and teaching at Harvard and UCLA in the first 20 years of his career. Fareed returned to clinical medicine in 1991 when he came to the Imperial Valley to establish a general practice.

No one who knows him well was surprised to see him jump into the COVID-19 pandemic full force. As hot spots jumped from city to city, cases and deaths rose, businesses and schools closed down, Fareed began testing for the virus, followed by caring for patients at home, in the hospitals, and in the local COVID-tents set up by the hospitals and the National Guard.

//

"I became so frustrated." Fareed said as he listened to national news and the Task Force. What he was hearing and what he witnessed first-hand did not correlate.

He began zoom meetings with other front-line doctors on the east coast and found they had the same experiences he did, finding what worked and what didn't, finding preventatives before exposures, and keeping his patients alive.

The frustration levels rose between Fareed and other doctors that action had to be taken, he said. Fareed has written letters to President Trump, Representative Juan Vargas, and the Presidential Task Force. He continues Zoom meetings with other doctors, and hope to get to Washington D.C. to share their knowledge and results.

Here is the letter Fareed sent to President Trump:

Dear President Trump and Task Force,

My name is Dr. George Fareed. I am a physician in Imperial County, California, that has been hit hard by the COVID-19 pandemic. I take care of patients on both an outpatient and inpatient basis, as well as nursing home patients, the most vulnerable among us.

In this letter, I am proposing a medical strategy that can help us not only through this current crisis, but also that will enable us to approach outbreaks of COVID-19 that may occur in the future.

In my attempts to keep people alive, I have had an opportunity to use many different types of treatments — remdesivir, dexamethasone, convalescent plasma replacement, etc.

Yet, by far the best tool beyond supportive care with oxygen has been the combination of hydroxychloroquine (HCQ), with either azithromycin or doxycycline, and zinc. This "HCQ cocktail" (that costs less than \$100) has enabled me to prevent patients from being admitted to the hospital, as well as help those patients that are hospitalized. **The key is giving the HCQ cocktail early, within the first five days of the disease.**

Not only have I seen outstanding results with this approach, I have not seen any patient exhibit serious side-effects. To be clear — this drug has been used as an anti-malarial and to treat systemic lupus erythematosus as well as rheumatoid arthritis, and has over a 50-year track record for safety. It is shocking that it only now is being characterized as a dangerous drug.

Moreover, I am in my seventies, and I (as well as some other older physicians in the hospital) use hydroxychloroquine and zinc as prophylaxis. None of us have contracted the disease despite our high exposure to COVID patients nor have we experienced any side-effects.

Despite the characterization in the mainstream media as the drug being "ineffective" and "dangerous," the evidence in the literature tells a different story. I am not only an "MD," but a former Harvard Medical School assistant professor and UCLA School of Medicine associate professor as well and am very competent at evaluating studies. There is ample evidence now that the HCQ cocktail is effective and there is no good evidence that there are significant side effects.

Yet, like many of my colleagues in the trenches treating COVID, I find myself being obstructed on different levels from treating my patients with hydroxychloroquine. The next option is remdesivir, which in my opinion is inferior and very expensive. Moreover, that drug is not readily available and is rationed by hospitals. Despite the representations by Dr. Fauci and others, there is less evidence supporting the use of remdesivir than hydroxychloroquine.

To be clear — hydroxychloroquine is normally not helpful when given to very ill patients. Unfortunately, most of the studies have evaluated this drug only in that context. The HCQ cocktail is best used to prevent patients from getting to that dire stage.

This is all so tragic because the use of HCQ cocktail would solve some of the very basic problems we are now facing:

The HCQ cocktail can be used for outpatients to prevent hospitalizations and thus keep our hospitals and ICUs from being overrun with COVID patients.

The HCQ cocktail can be used early on in hospitalization to prevent patients from requiring mechanical ventilation and reducing the length of hospital stay.

HCQ/zinc can be used for prophylaxis for high risk individuals including front line health providers, first responders, and even teachers who are at high risk for COVID.

As a physician, I am committed to my patients as well as doing my part to solve the COVID crisis. It has been deflating to see how the "science" has been corrupted and manipulated in an effort to disparage hydroxychloroquine. The fact that both Lancet and the New England Journal of Medicine had to retract articles relevant to hydroxychloroquine due to gross manipulation and mischaracterization of data goes to the heart of what is best characterized as a smear campaign.

As an example of the faulty science, one study (University of Minnesota) was cited in the mainstream media as disproving the effectiveness of hydroxychloroquine as "prophylaxis," yet the patients received the drug one to four days AFTER exposure. That is not prophylaxis at all — the drug must be taken PRIOR to exposure. This is just one example of the non-

scientific way the drug has been evaluated and the subsequent mainstream media mischaracterizations.

I am writing to you out of the frustration of knowing that there is a solution, but watching as our country flounders in dealing with COVID-19. In my opinion, tens of thousands are dying unnecessarily. Our current approach of waiting for these high-risk patients to become ill and then hospitalizing them is failing. The answer is early diagnosis of the high-risk individuals, and then treating them as outpatients with the HCQ cocktail to prevent hospitalization.

So, what I am proposing is a drastic shift from our current approach: we need to ramp up our outpatient efforts of treating COVID-19 to decrease the burden on hospitals and save lives. Such an approach requires an effective outpatient treatment — we have that in the HCQ cocktail.

How do we get there? I propose that the Task Force allow myself and a few other clinicians/researchers who have used and/or studied the HCQ cocktail present our plan that focuses on outpatient treatment and prevention as opposed to a hospital-based approach only treating patients when they become ill. The FDA and CDC should be there as well given that they are the agencies that formulate the drug policies.

We need a medical strategy, not only for now while we are in a crisis, but for the future. There is no guarantee that a vaccine will rid us of COVID-19. If we had a strategy, we would not have to shut down American life, especially schools, every time there is an outbreak.

We should be seeking a solution that will save as many lives as possible, and the outpatient-based approach that I and some other doctors have been advocating will best accomplish that goal.

I hope you consider my proposal, and I look forward to hearing from you.

Sincerely yours,

George C. Fareed, M.D.